Sangamo Therapeutics said on Monday it would regain the rights to its hemophilia A gene therapy following the termination of a co-development agreement with partner Pfizer, sending its shares down 30.3% in extended trading.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,